Peck, R., & Norris, C. W. (2012). Significant Risks of Oral Contraceptives (OCPs): Why This Drug Class Should Not Be Included in a Preventive Care Mandate. The Linacre Quarterly, 79(1), 41-56. https://doi.org/10.1179/002436312803571447
Peck R, Norris CW. Significant Risks of Oral Contraceptives (OCPs): Why This Drug Class Should Not Be Included in a Preventive Care Mandate. Linacre Q. 2012;79(1):41-56. doi:10.1179/002436312803571447
Peck, Rebecca, and Charles W. Norris. "Significant Risks of Oral Contraceptives (OCPs): Why This Drug Class Should Not Be Included in a Preventive Care Mandate." The Linacre Quarterly, vol. 79, no. 1, 2012, pp. 41-56.
Oral contraceptives raise clot and cancer risk, two physicians argue
A narrative review by two physicians argues that oral contraceptives raise the risk of blood clots, breast cancer and cervical cancer. Their summary covers clots, stroke, heart attack and two cancers.
Key Findings
The authors report a three to five times higher clot risk, called venous thromboembolism (VTE), associated with oral contraceptive use.
In a Danish comparison with levonorgestrel pills at the same estrogen dose, the rate ratio for clots was 1.82 with desogestrel, 1.86 with gestodene and 1.64 with drospirenone.
A meta-analysis of fifty-four epidemiological studies (53,297 women with breast cancer, 100,239 controls) found a relative risk of 1.24 in current users and 1.95 for use before age twenty.
A meta-analysis of thirty-four case-control studies found an odds ratio of 1.19 for premenopausal breast cancer, 1.44 with use before a first full-term pregnancy, and 1.52 beyond four years of use.
In more developed countries, a 2007 Lancet reanalysis estimated that ten years of use from around age twenty to thirty raises invasive cervical cancer incidence by age fifty from 3.8/1,000 to 4.5/1,000.
Interpretation
This narrative review by two physicians gathers case-control, cohort and meta-analysis data linking oral contraceptive use to clot, stroke, heart attack and cancer risk. The authors note that the breast cancer question needs randomized controlled trials. The findings support larger, controlled studies of oral contraceptive risk across progestin types and life stages.
RRM Context
Oral contraceptives are suppressive medications. They suppress ovulation, which the authors call a normal body process. Restorative Reproductive Medicine reads the ovulatory cycle as a vital sign and looks for the underlying cause of cycle symptoms. Suppression hides symptoms very well while disease can progress.
Our editorial summary of this paper, not the article's abstract.
Abstract
Pregnancy is not a disease. But more fundamentally, neither is human fertility. They are normal physiologic processes of the sexually mature person. By classifying pregnancy and fertility as disease states, certain entities are able to position contraception as "the cure." Currently, these same organizations want to include oral contraceptive counseling and medications in the new national health-care plan under a preventive care mandate. But it is the physician's role to counsel patients on preventive care measures. We understand that these evidenced-based screenings help to change risky behaviors and catch disease in its earliest stages, thereby reducing patients' overall morbidity and mortality. However, we believe that patients incur substantial health risks when choosing oral contraceptives (OCPs). This paper reviews the major risks of OCPs. The authors presume that the prevailing widespread acceptance and promotion of OCPs indicates general agreement within the medical community that OCPs are good for the patient (or at least not significantly harmful). Therefore, this paper concentrates on the studies which show increased harm and risk to the patient choosing to use OCPs. We have concentrated our efforts on three major areas: increased rates of cardiovascular disease, breast cancer, and human papillomavirus (HPV) or cervical cancer. If fertility and pregnancy are not disease states, and are, in fact, normal conditions associated with healthy individuals, OCPs fail the most important test of preventive medicine: they increase risk of disease instead of decreasing it. Patients should not be misled or confused into believing that what they are taking is "good for them" and is of the same beneficial effect as other preventive measures.